tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Jun 30;8(7)
fab339.
doi: 10.1093/ofid/ofab339. eCollection 2021 Jul.
Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
Akshay Khatri[SUP] 1 [/SUP], Prashant Malhotra[SUP] 1 [/SUP], Stephanie Izard[SUP] 2 [/SUP], Angela Kim[SUP] 1 [/SUP], Michael Oppenheim[SUP] 1 [/SUP], Pranisha Gautam-Goyal[SUP] 1 [/SUP], Thomas Chen[SUP] 1 [/SUP], Thien-Ly Doan[SUP] 3 [/SUP], Ilan Berlinrut[SUP] 1 [/SUP], Negin Niknam[SUP] 1 [/SUP], Sarah Flannery[SUP] 1 [/SUP], David Hirschwerk[SUP] 1 [/SUP], Marcia Epstein[SUP] 1 [/SUP], Bruce Farber[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Immunosuppressive therapies proposed for Coronavirus disease 2019 (COVID-19) management may predispose to secondary infections. We evaluated the association of immunosuppressive therapies with bloodstream-infections (BSIs) in hospitalized COVID-19 patients.
Methods: This was an institutional review board-approved retrospective, multicenter, cohort study of adults hospitalized with COVID-19 over a 5-month period. We obtained clinical, microbiologic and laboratory data from electronic medical records. Propensity-score-matching helped create balanced exposure groups. Demographic characteristics were compared across outcome groups (BSI/no BSI) using two-sample t-test and Chi-Square test for continuous and categorical variables respectively, while immunosuppressive therapy use was compared using McNemar's test. Conditional logistic regression helped assess the association between immunosuppressive therapies and BSIs.
Results: 13,007 patients were originally included, with propensity-score-matching producing a sample of 6,520 patients. 3.74% and 3.97% were diagnosed with clinically significant BSIs in the original and propensity-score-matched populations respectively. COVID-19 patients with BSIs had significantly longer hospitalizations, higher intensive care unit admission and mortality rates compared to those without BSIs. On univariable analysis, combinations of corticosteroids/anakinra [odds-ratio (OR) 2.00, 95% confidence intervals (C.I.) 1.05-3.80, P value.0342] and corticosteroids/tocilizumab [OR 2.13, 95% C.I. 1.16-3.94, P value .0155] were significantly associated with BSIs. On multivariable analysis (adjusting for confounders), combination corticosteroids/tocilizumab were significantly associated with any BSI [OR 1.97, 95% C.I. 1.04-3.73, P value.0386] and with bacterial BSIs [OR 2.13, 95% C.I. 1.12-4.05, p-value 0.0217].
Conclusions: Combination immunosuppressive therapies were significantly associated with BSI occurrence in COVID-19 patients; their use warrants increased BSI surveillance. Further studies are needed to establish their causative role.
Keywords: COVID-19; SARS-CoV-2; bacteremia; fungemia; immunosuppressive therapy.
. 2021 Jun 30;8(7)
fab339.doi: 10.1093/ofid/ofab339. eCollection 2021 Jul.
Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
Akshay Khatri[SUP] 1 [/SUP], Prashant Malhotra[SUP] 1 [/SUP], Stephanie Izard[SUP] 2 [/SUP], Angela Kim[SUP] 1 [/SUP], Michael Oppenheim[SUP] 1 [/SUP], Pranisha Gautam-Goyal[SUP] 1 [/SUP], Thomas Chen[SUP] 1 [/SUP], Thien-Ly Doan[SUP] 3 [/SUP], Ilan Berlinrut[SUP] 1 [/SUP], Negin Niknam[SUP] 1 [/SUP], Sarah Flannery[SUP] 1 [/SUP], David Hirschwerk[SUP] 1 [/SUP], Marcia Epstein[SUP] 1 [/SUP], Bruce Farber[SUP] 1 [/SUP]
Affiliations
- PMID: 34337096
- PMCID: PMC8320294
- DOI: 10.1093/ofid/ofab339
Abstract
Background: Immunosuppressive therapies proposed for Coronavirus disease 2019 (COVID-19) management may predispose to secondary infections. We evaluated the association of immunosuppressive therapies with bloodstream-infections (BSIs) in hospitalized COVID-19 patients.
Methods: This was an institutional review board-approved retrospective, multicenter, cohort study of adults hospitalized with COVID-19 over a 5-month period. We obtained clinical, microbiologic and laboratory data from electronic medical records. Propensity-score-matching helped create balanced exposure groups. Demographic characteristics were compared across outcome groups (BSI/no BSI) using two-sample t-test and Chi-Square test for continuous and categorical variables respectively, while immunosuppressive therapy use was compared using McNemar's test. Conditional logistic regression helped assess the association between immunosuppressive therapies and BSIs.
Results: 13,007 patients were originally included, with propensity-score-matching producing a sample of 6,520 patients. 3.74% and 3.97% were diagnosed with clinically significant BSIs in the original and propensity-score-matched populations respectively. COVID-19 patients with BSIs had significantly longer hospitalizations, higher intensive care unit admission and mortality rates compared to those without BSIs. On univariable analysis, combinations of corticosteroids/anakinra [odds-ratio (OR) 2.00, 95% confidence intervals (C.I.) 1.05-3.80, P value.0342] and corticosteroids/tocilizumab [OR 2.13, 95% C.I. 1.16-3.94, P value .0155] were significantly associated with BSIs. On multivariable analysis (adjusting for confounders), combination corticosteroids/tocilizumab were significantly associated with any BSI [OR 1.97, 95% C.I. 1.04-3.73, P value.0386] and with bacterial BSIs [OR 2.13, 95% C.I. 1.12-4.05, p-value 0.0217].
Conclusions: Combination immunosuppressive therapies were significantly associated with BSI occurrence in COVID-19 patients; their use warrants increased BSI surveillance. Further studies are needed to establish their causative role.
Keywords: COVID-19; SARS-CoV-2; bacteremia; fungemia; immunosuppressive therapy.